Does VAS-101 solve a long-standing delivery problem in curcumin-based osteoarthritis treatment?
Vascarta’s VAS-101 showed early knee osteoarthritis pain benefits. Read what the data changes, what remains unclear, and what to watch next.
What Caliway’s CBL-514 and tirzepatide combination data could reveal about obesity treatment next
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
What Glenmark Pharmaceuticals’ Ryaltris commercialization shift means for allergy drug competition
Glenmark Pharmaceuticals is taking direct control of Ryaltris in the U.S. Read what this shift means for allergy drug strategy and specialty growth.
Why AvenCell Therapeutics is using AVC-203 to test whether allogeneic CAR-T can move beyond manufacturing bottlenecks
AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.
Why PanGIA Biotech’s urine biopsy data may matter more than the headline sensitivity figure suggests
PanGIA Biotech reported 97.8% sensitivity in a urine-based prostate cancer study. Read what the data changes and what risks still remain.
How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story
Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.
What Accent Therapeutics’ AACR 2026 ATX-295 update reveals about the next wave of precision oncology targets
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.
Is Nuvation Bio building the next IDH1 glioma contender with safusidenib and SIGMA?
Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.
Scinai Immunotherapeutics doubles CDMO revenue, but can the Recipharm deal change the bigger picture?
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.